FRIDAY, Jan. 7 (HealthDay News) -- The Infectious Diseases Society of America has assembled the first guidelines for the treatment of methicillin-resistant Staphylococcus aureus (MRSA), published online Jan. 4 in Clinical Infectious Diseases.
Catherine Liu, M.D., of the University of California in San Francisco, and colleagues reviewed hundreds of scientific studies, papers, and presentations to assemble evidence-based guidelines for health care providers in the management of adult and pediatric patients with MRSA infections.
The guidelines address MRSA-related syndromes such as skin and soft tissue infections, bacteremia and endocarditis, pneumonia, bone and joint infections, and central nervous system infections. Recommendations are provided for the use of vancomycin and other antibiotics, and guidance is provided for the management of invasive infections and treatment of babies born with MRSA infections.
"MRSA has become a huge public health problem and physicians often struggle with how to treat it," Liu said in a statement. "The guidelines establish a framework to help physicians determine how to evaluate and treat uncomplicated as well as invasive infections. It's designed to be a living document, meaning the recommendations will evolve as new information and antibiotics become available."
Several authors disclosed financial relationships with pharmaceutical and/or medical device companies.
Abstract
Full Text (subscription or payment may be required)
